Table 1.

Patient characteristics

	BEAM n = 174	BeEAM n = 63	p-value
Age, median (range)	46.5 (19.5–69.4)	45 (21.5–72.8)	0.91
Gender, male (%)/female (%)	104 (59.8)/70 (40.2)	37 (58.7)/26 (41.3)	0.89
Diagnosis, n (%):  HL  DLBCL  FL  MCL  MZL  BL  ALCL ALK+  ALCL ALK-  PTCL NOS  EATL  LBL	85 (48.8) 57 (32.8) 8 (4.6) 7 (4.0) 3 (1.7) 1 (0.6) 1 (0.6) 1 (0.6) 2 (1.1) 1 (0.6) 0	25 (39.7) 20 (31.7) 6 (9.5) 3 (4.8) 2 (3.2) 0 0 0 0 0 1 (1.6)	0.54
Remission status before HSCT (%):  CR1  CR2  CR > 2  PR1  PR2  NR/PD	70 (40.2) 32 (18.4) 2 (1.4) 49 (28.2) 2 (1.1) 15 (8.6)	25 (39.7) 7 (11.1) 2 (3.2) 18 (28.6) 1 (1.6) 10 (15.9)	0.31
CD34+ cell dose (× 106/kg), median (range)	5.1 (1.5–42.6)	4.1 (2.0–16.8)	0.007

HL – Hodgkin lymphoma; DLBCL – diffused large B-cell lymphoma; FL – follicular lymphoma; MCL – mantle cell lymphoma; MZL – marginal zone lymphoma; BL – Burkitt lymphoma; ALCL ALK+ – anaplastic large T-cell lymphoma ALK-positive; ALCL ALK– anaplastic large T-cell lymphoma ALK-negative; PTCL NOS – peripheral T-cell lymphoma not otherwise specified; EATL – enteropathy associated T-cell lymphoma; LBL – lymphoblastic lymphoma; CR – complete remission; PR – partial remission; NR – non-remission; PD – progressive disease